Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young HOPE: Response-Guided Therapy Following Neoadjuvant Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer
NCT07671885Phase 3Recruiting
- Sponsor
- Tokyo Women's Medical University
- Start
- Jan 2026
- Primary completion
- Jan 2038
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Tokyo Women's Medical University. Primary endpoint: Event-Free Survival at 12 years. Started Jan 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07671885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671885.